VKTX – Viking Therapeutics, Inc.
Viking Therapeutics, Inc.VKTX
$33.45Name : Viking Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,761,284,096.00
EPSttm : -1.54
Viking Therapeutics, Inc.
$33.45
6.07%$1.92Float Short %
24.76
Margin Of Safety %
Put/Call OI Ratio
0.24
EPS Next Q Diff
-0.15
EPS Last/This Y
-1.33
EPS This/Next Y
-0.65
Price
31.54
Target Price
93.93
Analyst Recom
1.12
Performance Q
3.73
Relative Volume
0.82
Beta
0.6
Ticker: VKTX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | VKTX | 25.49 | 0.23 | 0.17 | 271979 |
| 2025-09-09 | VKTX | 25.28 | 0.23 | 0.25 | 278985 |
| 2025-09-10 | VKTX | 25.8 | 0.24 | 0.12 | 282448 |
| 2025-09-11 | VKTX | 25.77 | 0.23 | 0.11 | 285299 |
| 2025-09-12 | VKTX | 24.81 | 0.23 | 0.22 | 287630 |
| 2025-09-15 | VKTX | 24.08 | 0.22 | 0.25 | 282928 |
| 2025-09-16 | VKTX | 23.69 | 0.22 | 0.25 | 289358 |
| 2025-09-17 | VKTX | 23.09 | 0.21631664041297 | 0.20048669440301 | 292647 |
| 2025-09-18 | VKTX | 26.04 | 0.21 | 0.21 | 297251 |
| 2025-09-22 | VKTX | 26.24 | 0.21 | 0.14 | 254570 |
| 2025-09-23 | VKTX | 24.99 | 0.21 | 0.32 | 266860 |
| 2025-09-24 | VKTX | 26.62 | 0.22 | 0.18 | 271506 |
| 2025-09-25 | VKTX | 25.09 | 0.21 | 0.25 | 277485 |
| 2025-09-26 | VKTX | 25.44 | 0.22 | 0.41 | 279280 |
| 2025-09-29 | VKTX | 25.81 | 0.21 | 0.27 | 264666 |
| 2025-09-30 | VKTX | 26.3 | 0.22 | 0.25 | 273298 |
| 2025-10-01 | VKTX | 27.37 | 0.22 | 0.32 | 276951 |
| 2025-10-02 | VKTX | 27.73 | 0.23 | 0.36 | 280341 |
| 2025-10-03 | VKTX | 29.73 | 0.23 | 0.16 | 284086 |
| 2025-10-06 | VKTX | 32.26 | 0.23 | 0.18 | 264854 |
| 2025-10-07 | VKTX | 31.53 | 0.24 | 0.22 | 282566 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | VKTX | 25.48 | -204.6 | - | -2.33 |
| 2025-09-09 | VKTX | 25.25 | -206.6 | - | -2.34 |
| 2025-09-10 | VKTX | 25.88 | -206.6 | - | -2.34 |
| 2025-09-11 | VKTX | 25.74 | -206.6 | - | -2.34 |
| 2025-09-12 | VKTX | 24.82 | -206.6 | - | -2.34 |
| 2025-09-15 | VKTX | 24.08 | -206.6 | - | -2.34 |
| 2025-09-16 | VKTX | 23.69 | -206.6 | - | -2.34 |
| 2025-09-17 | VKTX | 23.08 | -206.6 | - | -2.34 |
| 2025-09-18 | VKTX | 26.04 | -206.6 | - | -2.34 |
| 2025-09-19 | VKTX | 25.38 | -206.6 | - | -2.34 |
| 2025-09-22 | VKTX | 26.25 | -206.6 | - | -2.34 |
| 2025-09-23 | VKTX | 24.98 | -206.6 | - | -2.34 |
| 2025-09-24 | VKTX | 26.63 | -206.6 | - | -2.34 |
| 2025-09-25 | VKTX | 25.09 | -206.6 | - | -2.34 |
| 2025-09-26 | VKTX | 25.57 | -206.6 | - | -2.34 |
| 2025-09-29 | VKTX | 25.82 | -206.6 | - | -2.34 |
| 2025-09-30 | VKTX | 26.28 | -206.6 | - | -2.34 |
| 2025-10-01 | VKTX | 27.38 | -206.6 | - | -2.34 |
| 2025-10-02 | VKTX | 27.84 | -206.6 | - | -2.34 |
| 2025-10-03 | VKTX | 29.72 | -206.6 | - | -2.34 |
| 2025-10-06 | VKTX | 32.27 | -206.6 | - | -2.34 |
| 2025-10-07 | VKTX | 31.54 | -206.6 | - | -2.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | VKTX | -1.01 | -1.77 | 25.22 |
| 2025-09-09 | VKTX | -1.01 | -1.77 | 25.22 |
| 2025-09-10 | VKTX | -1.01 | -1.77 | 25.22 |
| 2025-09-11 | VKTX | -1.01 | -1.77 | 24.45 |
| 2025-09-12 | VKTX | -1.01 | -1.77 | 24.45 |
| 2025-09-15 | VKTX | -1.01 | -1.75 | 24.45 |
| 2025-09-16 | VKTX | -1.01 | -1.75 | 24.45 |
| 2025-09-17 | VKTX | -1.01 | -1.75 | 24.45 |
| 2025-09-18 | VKTX | -1.01 | -1.75 | 24.45 |
| 2025-09-19 | VKTX | -1.01 | -1.75 | 24.45 |
| 2025-09-22 | VKTX | -1.01 | -1.79 | 24.45 |
| 2025-09-23 | VKTX | -1.01 | -1.79 | 24.45 |
| 2025-09-24 | VKTX | -1.01 | -1.79 | 24.45 |
| 2025-09-25 | VKTX | -1.01 | -1.79 | 24.76 |
| 2025-09-26 | VKTX | -1.01 | -1.79 | 24.76 |
| 2025-09-29 | VKTX | -1.01 | -1.77 | 24.76 |
| 2025-09-30 | VKTX | -1.01 | -1.77 | 24.76 |
| 2025-10-01 | VKTX | -1.01 | -1.77 | 24.76 |
| 2025-10-02 | VKTX | -1.01 | -1.77 | 24.76 |
| 2025-10-03 | VKTX | -1.05 | -1.77 | 24.76 |
| 2025-10-06 | VKTX | -1.05 | -1.26 | 24.76 |
| 2025-10-07 | VKTX | -1.05 | -1.26 | 24.76 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.58
Avg. EPS Est. Current Quarter
-0.67
Avg. EPS Est. Next Quarter
-0.73
Insider Transactions
-1.05
Institutional Transactions
-1.26
Beta
0.6
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
11
Growth Score
18
Sentiment Score
45
Actual DrawDown %
68.3
Max Drawdown 5-Year %
-78.9
Target Price
93.93
P/E
Forward P/E
PEG
P/S
P/B
4.45
P/Free Cash Flow
EPS
-1.53
Average EPS Est. Cur. Y
-2.34
EPS Next Y. (Est.)
-2.99
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.82
Return on Equity vs Sector %
-46.8
Return on Equity vs Industry %
-33.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Viking Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 48
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today
news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics, Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading